Intellia Therapeutics NTLA Return on equity

Return on equity at other companies

Ionis PharmaceuticalsIONS

-105.5%+336pp

ALN

Alnylam PharmaceuticalsALNY

91.4%—

CRISPR TherapeuticsCRSP

-31.2%+43.7pp

Beam TherapeuticsBEAM

-47.1%—

Design Therapeutics, Inc.DSGN

-31.3%+19.5pp

Prime MedicinePRME

-373.3%-1,281pp

FAQ

What is Intellia Therapeutics's return on equity?

Intellia Therapeutics (NTLA) reported return on equity of -56.3% in Q1 2026.

How has Intellia Therapeutics's return on equity changed year-over-year?

Intellia Therapeutics's return on equity increased by 2.7% year-over-year, from -57.9% to -56.3%.

What is the long-term trend for Intellia Therapeutics's return on equity?

Over 5 years (2020 to 2025), Intellia Therapeutics's return on equity has grown at a 9.7% compound annual growth rate (CAGR), from -33.7% to -53.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.